Inovio Pharmaceuticals Inc (NASDAQ:INO) CEO Jong Joseph Kim bought 22,500 shares of the stock in a transaction on Monday, January 13th. The shares were acquired at an average cost of $3.11 per share, for a total transaction of $69,975.00. Following the completion of the transaction, the chief executive officer now directly owns 1,100,707 shares of the company’s stock, valued at $3,423,198.77. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of NASDAQ:INO traded up $0.22 during midday trading on Monday, hitting $3.33. The company’s stock had a trading volume of 1,266,165 shares, compared to its average volume of 1,268,084. The stock has a market capitalization of $311.03 million, a price-to-earnings ratio of -3.17 and a beta of 2.22. The stock’s 50 day simple moving average is $2.89 and its 200 day simple moving average is $2.57. Inovio Pharmaceuticals Inc has a fifty-two week low of $1.91 and a fifty-two week high of $5.11. The company has a debt-to-equity ratio of 2.52, a quick ratio of 5.06 and a current ratio of 5.06.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.01. The company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $2.72 million. Inovio Pharmaceuticals had a negative return on equity of 179.91% and a negative net margin of 1,809.64%. During the same period last year, the business posted ($0.27) earnings per share. As a group, analysts anticipate that Inovio Pharmaceuticals Inc will post -1.08 EPS for the current year.
Several equities analysts have commented on INO shares. Piper Jaffray Companies lowered their target price on shares of Inovio Pharmaceuticals from $10.00 to $8.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Citigroup reaffirmed a “buy” rating and issued a $4.00 price target (down from $7.00) on shares of Inovio Pharmaceuticals in a research report on Monday, September 16th. Roth Capital started coverage on Inovio Pharmaceuticals in a research report on Thursday, December 19th. They issued a “buy” rating and a $13.00 price target on the stock. Maxim Group reaffirmed a “buy” rating on shares of Inovio Pharmaceuticals in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Inovio Pharmaceuticals in a research report on Monday, January 6th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $7.30.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Story: How to Invest in an Index Fund
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.